Mezquita, L., Planchard, D., Suarez, M. D., Aldea, M., Naltet, C., Lamberts, V., Grecea, M., Martin-Romano, P., de Kievit, F., Jovelet, C., Lacroix, L., Masip, J. R., Lavaud, P., Gazzah, A., Morris, C., Howarth, K., Green, E., Vassal, G., Massard, C., & Besse, B. (n.d.). 364OClinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC. Annals of oncology, 30, . http://access.bl.uk/ark:/81055/vdc_100098037804.0x00002c